UNSPSC 51422433: Hydrocortisone sodium phosphate

This classification denotes a therapeutic hydrocortisone with the molecular formula C21H29O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0388G963HY, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but more generally known as hydrocortisone sodium phosphate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02568MIG.

UNSPSC 51422433 Hydrocortisone sodium phosphate is a Commodity code that state and local procurement systems nominally identify with pharmaceutical products in the corticosteroid class. However, the recent opportunity record tagged to this code reflects a substantial mismatch: Seminole County, Florida posted an IFB (Invitation for Bid) for Naloxone and Safe Drug Deactivation Systems, a public-health procurement unrelated to hydrocortisone sodium phosphate. The code shows little relevant recent activity aligned with its stated pharmaceutical scope.

Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually via quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were required to submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs, hold drug-free workplace certification and E-Verify compliance, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract carried a two-year initial term with a one-year renewal option and a three-month probationary termination clause. The procurement potentially drew FEMA funding, triggering compliance with the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations for disadvantaged enterprises were specified. The mismatch between the code's pharmaceutical classification and the opportunity's harm-reduction focus signals that this Commodity code may not be a reliable indicator of active state and local procurement for hydrocortisone sodium phosphate.